230 related articles for article (PubMed ID: 34863313)
1. Clinical outcomes following intravitreal methotrexate for primary vitreoretinal lymphoma.
Anthony CL; Bavinger JC; Shantha JG; O'Keefe GD; Pearce WA; Voloschin A; Grossniklaus HE; Yeh S
Int J Retina Vitreous; 2021 Dec; 7(1):72. PubMed ID: 34863313
[TBL] [Abstract][Full Text] [Related]
2. A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma.
Zhou N; Xu X; Liu Y; Wang Y; Wei W
Eye (Lond); 2022 Jul; 36(7):1448-1455. PubMed ID: 34211136
[TBL] [Abstract][Full Text] [Related]
3. Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma.
Hashida N; Nakai K; Saitoh N; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):687-93. PubMed ID: 24549401
[TBL] [Abstract][Full Text] [Related]
4. High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma.
Akiyama H; Takase H; Kubo F; Miki T; Yamamoto M; Tomita M; Mochizuki M; Miura O; Arai A
Cancer Sci; 2016 Oct; 107(10):1458-1464. PubMed ID: 27412324
[TBL] [Abstract][Full Text] [Related]
5. Recurrent pseudohypopyon in association with primary vitreoretinal lymphoma: a case report.
Kitao M; Hashida N; Nishida K
BMC Ophthalmol; 2016 Jul; 16():103. PubMed ID: 27391815
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of intravitreal methotrexate to salvage eyes with relapsed primary intraocular lymphoma.
Mohammad M; Andrews RM; Plowman PN; Hay G; Arora AK; Cohen VML; Sagoo MS
Br J Ophthalmol; 2022 Jan; 106(1):135-140. PubMed ID: 33087316
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal observation of OCT imaging is a valuable tool to monitor primary vitreoretinal lymphoma treated with intravitreal injections of methotrexate.
Zhao H; Wang X; Mao Y; Peng X
BMC Ophthalmol; 2020 Jan; 20(1):10. PubMed ID: 31906917
[TBL] [Abstract][Full Text] [Related]
8. Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate.
Jiang T; Gu J; Liu S; Chang Q
BMC Ophthalmol; 2022 Sep; 22(1):375. PubMed ID: 36127675
[TBL] [Abstract][Full Text] [Related]
9. Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients.
Zhou X; Zhou X; Shi H; Lai J; Wang Q; Li Y; Chen K; Li Q; Zhou Q; Cao X; Chen B; Xiao J
BMC Ophthalmol; 2020 May; 20(1):189. PubMed ID: 32397978
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.
Frenkel S; Hendler K; Siegal T; Shalom E; Pe'er J
Br J Ophthalmol; 2008 Mar; 92(3):383-8. PubMed ID: 18303160
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of combined intravitreal methotrexate and systemic high-dose methotrexate therapy in vitreoretinal lymphoma.
Cheng CL; Yeh PT; Fang WQ; Ma WL; Hou HA; Tsai CH; Lin CP; Tien HF
Cancer Med; 2023 Apr; 12(7):8102-8111. PubMed ID: 36602288
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis, treatment, and prognosis of primary intraocular lymphoma: Single-center real-world clinical experience.
Min GJ; Kim TY; Jeon YW; O JH; Choi BO; Park G; Park YH; Cho SG
Cancer Med; 2023 Apr; 12(7):7911-7922. PubMed ID: 36721307
[TBL] [Abstract][Full Text] [Related]
13. Primary Vitreoretinal Lymphoma Therapy Monitoring: Significant Vitreous Haze Reduction After Intravitreal Rituximab.
Kakkassery V; Heindl LM; Rokohl AC; Chronopoulos A; Schutz JS; Ranjbar M; Schargus M; Böker A; Winterhalter S; Stübiger N
Neurosignals; 2021 May; 29(S1):1-7. PubMed ID: 33945240
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study.
Zhang Y; Zhang X; Zou D; Yin J; Zhang L; Wang X; Jia C; Wang W; Zhao D; Zhou D; Zhang W; Zhang M
Front Oncol; 2021; 11():701507. PubMed ID: 34249763
[TBL] [Abstract][Full Text] [Related]
15. Occlusive retinal vasculitis as a presenting feature of primary vitreoretinal lymphoma relapse.
Ketkar M; Sahoo N; Raval V
Retin Cases Brief Rep; 2024 Jan; ():. PubMed ID: 38166202
[TBL] [Abstract][Full Text] [Related]
16. Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma.
Motomura Y; Yoshifuji K; Tachibana T; Takase H; Arai A; Tanaka K; Okada K; Nogami A; Umezawa Y; Sakashita C; Yamamoto M; Mori T; Nagao T
Br J Haematol; 2024 Apr; 204(4):1279-1287. PubMed ID: 38131400
[TBL] [Abstract][Full Text] [Related]
17. Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.
Castellino A; Pulido JS; Johnston PB; Ristow KM; Nora Bennani N; Inwards DJ; Macon WR; Micallef INM; King RL; Salomao DR; Witzig TE; Habermann TM; Nowakowski GS
Am J Hematol; 2019 Mar; 94(3):291-298. PubMed ID: 30516868
[TBL] [Abstract][Full Text] [Related]
18. Case 01-2017 - Primary vitreoretinal lymphoma (PVRL): report of a case and update of literature from 1942 to 2016.
Wang Y; Cheung DS; Chan CC
Ann Eye Sci; 2017 Jul; 2():. PubMed ID: 30167573
[TBL] [Abstract][Full Text] [Related]
19. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement.
Smith JR; Rosenbaum JT; Wilson DJ; Doolittle ND; Siegal T; Neuwelt EA; Pe'er J
Ophthalmology; 2002 Sep; 109(9):1709-16. PubMed ID: 12208721
[TBL] [Abstract][Full Text] [Related]
20. Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study.
Lam M; Touitou V; Choquet S; Cassoux N; Ghesquières H; Kodjikian L; Schmitt A; Gattoussi S; Tabouret É; Sampo M; Blonski M; Angioi-Duprez K; Houot R; Mouriaux F; Gyan E; Le Lez ML; Moles MP; Croisé F; Chauchet A; Schwartz C; Ahle G; Meyer L; Gressin R; Chiquet C; Oberic L; Ollé P; Marolleau JP; Jany B; Tempescul A; Cochener B; Damaj G; Quintyn JC; Moluçon-Chabrot C; Rousseau E; Franciane P; Schneider C; Massé H; Tamburini-Bonnefoy J; Brézin A; Fornecker LM; Ballonzoli L; Le Garff-Tavernier M; Hoang-Xuan K; Bodaghi B; Soussain C; Houillier C
Am J Hematol; 2021 Jul; 96(7):823-833. PubMed ID: 33864703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
